SEARCH

SEARCH BY CITATION

References

  • 1
    Schett G, Coates LE, Ash ZR et al. (2011) Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 13(Suppl. 1), S4.
  • 2
    Galloway JB, Hyrich KL, Mercer LK et al. (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50, 12431.
  • 3
    Nordgaard-Lassen I, Dahlerup JF, Belard E et al. (2012) Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J 59, C4480.
  • 4
    Mori S (2011) Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 21, 6217.
  • 5
    Arnett FC, Edwarthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 31524.
  • 6
    Dass S, Vital EM, Emery P (2006) Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 7, 255970.
  • 7
    Kato T, Ubara Y, Sawa N et al. (2004) A case of rheumatoid arthritis exhibiting accelerating rheumatoid pleurisy during low-dose weekly methotrexate therapy. Mod Rheumatol 14, 4148.
  • 8
    Sanmarti R, Gomez CA, Ercilla G et al. (2007) Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 26, 11118.
  • 9
    Weinblatt ME, Schiff MH, Ruderman EM et al. (2008) Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 58, 192130.
  • 10
    Park MC, Jung SJ, Park YB et al. (2008) Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol 37, 1738.
  • 11
    Alonso-Ruiz A, Pijoan JI, Ansuategui E et al. (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. BMC Musculoskelet Disord 9, 52.
  • 12
    Lu ZH, Chen W, Ju ZC et al. (2011) Pathological features and prognosis in chronic hepatitis B virus carriers. J Int Med Res 39 (1), 717.
  • 13
    Esteve M, Saro C, González-Huix F et al. (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53, 13635.
  • 14
    Roux CH, Brocq O, Breuil V et al. (2006) Safety of anti-TNF-a therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45, 12947.
  • 15
    Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum 59, 76284.
  • 16
    Kasahara S, Ando K, Saito K et al. (2003) Lack of tumor necrosis factor _ induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 77, 246976.
  • 17
    Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21, 136671.
  • 18
    Rahier JF, Ben-Horin S, Chowers Y et al. (2009) European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 3 (2), 4791.
  • 19
    Lok ASF, McMahon BJ (2009) AASLD Practice Guidelines update- Chronic Hepatitis B: Update. Hepatology 50 (3), 136.
  • 20
    Verhelst X, Orlent H, Colle I et al. (2010) Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 22, 4949.